TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Complexa raises $13M to fund trials of kidney disease drug

Email Newsletters

Click here to sign up for one of our email newsletters.

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

Wednesday, June 4, 2014, 10:51 a.m.
 

Complexa Inc., a South Side-based drug development company, said it raised $13 million from investors that will fund clinical trials of a drug to treat kidney disease.

The funding round, Complexa's second, was led by Jafco Life Science Investment, an arm of Japanese private equity firm Jafco Co. Ltd.

The company previously raised more than $8 million from venture capital investors to license and develop molecules discovered and patented by professor Bruce Freeman and a team of researchers at the University of Pittsburgh.

There is “great interest” in Complexa's work from large pharmaceutical companies, Jafco officials said in a statement.

Add Alex Nixon to your Google+ circles.

Subscribe today! Click here for our subscription offers.

 

 

 


Show commenting policy

Most-Read Business Headlines

  1. Pittsburgh’s tech startup activity rates last of 40 metro areas in report
  2. After years of downsizing, big houses make comeback
  3. New J.C. Penney CEO comes from middle-income America
  4. Floating homes offer ‘affordable’ option in San Francisco area
  5. How to land that 1st job after college
  6. Corporate America speaking out on social issues, getting results
  7. Pending home sales in U.S. climb to 9-year high
  8. Truffle dogs sniff out pungent fungus prized by foodies
  9. Obama overtime proposal slammed
  10. McDonald’s localizes menus to battle growing competition
  11. Heinz executives to dominate post-merger management of Kraft Heinz Co.